Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia
In a phase 3, double-blind, noninferiority trial, ceftobiprole's effectiveness was compared with daptomycin for treating complicated Staphylococcus aureus bacteremia, including the methicillin-resistant strains. The study population comprised 390 patients, 387 of whom had confirmed S. aureus bacteremia. The primary outcome was to determine overall treatment success 70 days post-randomization. Both drugs demonstrated comparable effectiveness, with ceftobiprole proving to be noninferior to daptomycin. Notably, the occurrence of adverse events was similar between the two treatment groups, although gastrointestinal issues, primarily mild nausea, appeared more frequent in the ceftobiprole group.
Conclusions:
Ceftobiprole demonstrates noninferiority when compared to daptomycin in the treatment of patients with complicated S. aureus bacteremia. The overall safety profiles of both drugs were comparable, though a higher incidence of gastrointestinal issues, especially mild nausea, was noted with ceftobiprole.
